We are live on ! Find out more
FTH

Faeth Therapeutics
FTH

23 hedge funds and large institutions have $2.05M invested in Faeth Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more funds holding

Funds holding: 21 → 23 (+2)

0.15% more ownership

Funds ownership: 11.7% → 11.85% (+0.15%)

14% less capital invested

Capital invested by funds: $2.38M → $2.05M (-$331K)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
23
Holders Change
+2
Holders Change %
+9.52%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
5
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$40.7K
2
Citadel Advisors
Citadel Advisors
Florida
+$17.6K
3
TRCT
Tower Research Capital (TRC)
New York
+$805
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$205

Top Sellers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
-$156K
2
Millennium Management
Millennium Management
New York
-$13K
3
Two Sigma Investments
Two Sigma Investments
New York
-$478
4
BlackRock
BlackRock
New York
-$273
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$273

FTH Hedge Fund Activity: Q4 2023 in Review

23 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q4 2023, worth a combined $2.05M — down 14% from $2.38M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new FTH positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 5 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $40.7K. The largest seller was Newtyn Management, cutting an estimated $156K.

  • 23 institutional investors held Faeth Therapeutics (FTH) as of Q4 2023, up from 21 in Q3 2023.
  • Funds reported $2.05M of Faeth Therapeutics stock for Q4 2023, down 14% quarter-over-quarter.
  • 2 funds opened new Faeth Therapeutics positions in Q4 2023 and 0 closed out, a net change of +2 holders.
  • The largest Faeth Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $40.7K added.
  • The largest Faeth Therapeutics seller in Q4 2023 was Newtyn Management, an estimated $156K sold.

Based on aggregated 13F filings for Q4 2023.